Metastatic virilizing adrenocortical carcinoma: A rare case of cure with surgery and mitotane therapy

7Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

A 57-year-old white woman with metastases to lungs and liver from virilizing adrenocortical carcinoma (ACC) was treated with radical nephroadrenalectomy followed by oral mitotane 3 to 6 g/day for 5 months. She developed complete response and remained free of disease for more than 25 years. Here we present the case and review the literature. ACC is a rare tumor and may occur at any age. About 60% are functional tumors with hormonal secretions and clinical manifestations due to specific hormone secretions: Cushing's syndrome due to cortisone, virilizing tumor due to androgens, feminizing tumor due to estrogens, or hypertension due to aldosterone. Stage I and II disease is curable with surgery. Stage III and IV disease may benefit from mitotane orally with gradual adjustment of the dosage to a tolerable level. Plasma mitotane level at 14 to 20 g/L results in optimal response both in hormonal secretion and symptom control, as well as tumor regression. Addition of chemotherapy (streptozotocin or a combination of etoposide, cisplatin and doxorubicin) to mitotane also produced responses along with increased survival among responders. An international study has been started by randomizing between two of the above combinations by the Collaborative Group for Adrenocortical Carcinoma Treatment. © 2009 Marshfield Clinic.

Cite

CITATION STYLE

APA

Chalasani, S., Vats, H. S., Banerjee, T. K., & McKenzie, A. K. (2009). Metastatic virilizing adrenocortical carcinoma: A rare case of cure with surgery and mitotane therapy. Clinical Medicine and Research, 7(1–2), 48–51. https://doi.org/10.3121/cmr.2009.821

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free